BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Integrated DNA Technologies Release: miRNA Regulated Networks Identified in Cystic Fibrosis


5/21/2013 9:29:42 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CORALVILLE, IA – 21 May 2013 – Integrated DNA Technologies (IDT), the world leader in oligonucleotide synthesis, offers insight into recent research that has unearthed an miRNA-regulated network implicated in the pathogenesis of Cystic Fibrosis (CF). Described in the April edition of DECODED, the international IDT customer newsletter, optimized DIG-labeled DsiRNAs (IDT) were used to develop a novel, enhanced approach for oligonucleotide delivery. Using this delivery technology, researchers led by Dr Paul McCray and Dr Beverly Davidson (Department of Pediatrics, Carver College of Medicine, University of Iowa, IA, USA) showed that the introduction of an miR-138 mimic, developed by IDT, resulted in knockdown of the transcriptional regulator SIN3A, subsequently leading to improved CFTR anion channel functionality on the cell surface, and a partially rescued phenotype.

The discovery sheds light on a previously unrecognized mechanism of CFTR processing, and opens up exciting possibilities for novel therapeutic targets in CF. Dr McCarthy commented on the strength of the collaboration with IDT, observing how the quality of the oligos remained intact for the entirety of the experiments, and provided them with “a really robust tool to look at the questions we were asking”.

To read the complete article, please see the April 3.2 issue of DECODED.

For more information please visit www.idtdna.com. Follow us on twitter @idtdna for real-time updates and insights.

About IDT

Integrated DNA Technologies (IDT) is the largest supplier of custom nucleic acids in the world, serving academic, government, and commercial researchers in biotechnology, clinical diagnostics, and pharmaceutical development. IDT's primary business is the manufacture of custom, synthetic DNA and RNA oligonucleotides. Today, IDT synthesizes and ships an average of 36,000 custom oligos per day to more than 86,000 customers worldwide. IDT manufacturing locations include facilities in Coralville, Iowa; San Diego, Calif.; Leuven, Belgium; and Singapore. For more information visit www.idtdna.com.

Integrated DNA Technologies

800-328-2661 (US & Canada)

+1 319-626-8400 (outside US)

productinfo@idtdna.com

www.idtdna.com



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES